Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is used in fibrotic lung disorders and certain cancers, targeting pathways that drive fibroblast activity and tumor angiogenesis. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilises respiratory status. - Non‑small cell lung cancer (with appropriate companion therapy): inhibits tumour growth and angiogenesis, contributing to disease control.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhoea - Abdominal pain - Decreased appetite - Vomiting - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Severe liver injury - Bleeding events - Arterial thromboembolic episodes - Hypertension - Gastrointestinal perforation - Severe infections

Before initiating therapy, clinicians should assess several safety parameters. - Liver function monitoring: check ALT/AST before and during treatment. - Bleeding risk: avoid concomitant anticoagulants unless clearly indicated. - Cardiovascular assessment: evaluate for hypertension and arterial events. - Gastrointestinal health: monitor for signs of perforation or severe diarrhoea. - Pregnancy and lactation: use only if benefits outweigh potential risks; safety not established. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensives: may require dose adjustment due to blood‑pressure changes. - Diuretics: monitor electrolytes if combined with gastrointestinal fluid loss.